Meeting the complex needs of young patients

The ICR and The Royal Marsden are leaders in the research and development of new drugs to tackle childhood cancers


children aged 14 or under are diagnosed with cancer each year

The BRC increases young patients’ access to the latest treatments and clinical trials

Personalised treatments

The number of Phase I and II paediatric drug trials conducted at The Royal Marsden increased from seven in 2009 to 23 in 2016

Professor Louis Chesler

Innovative trials

"I hope that through this initiative, we can drive forward the best possible use of targeted drugs in children"